- Home
- ANGH vs INMB Comparison
ANGH vs INMB Comparison
Compare ANGH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | INMB |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United Arab Emirates | United States |
| Employees | 186 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 37.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANGH | INMB |
|---|---|---|
| Price | $3.54 | $1.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 7.1K | ★ 464.1K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.25 | $1.09 |
| 52 Week High | $7.05 | $11.64 |
Technical Indicators
Market Signals| Indicator | ANGH | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 42.29 |
| Support Level | $2.79 | $1.15 |
| Resistance Level | $3.57 | $1.51 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 57.87 | 2.06 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.